Skip to main content

Mustang Bio, Inc.

corporate_fare Company Profile

Mustang Bio, Inc.

MBIO·NASDAQ·Life Sciences·CIK 0001680048

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing potential cures for difficult-to-treat cancers. The company acquires rights to medical technologies through licensing or ownership, funds their research and development, and then either out-licenses them or brings them to market. Mustang's current development pipeline is focused on novel therapies for solid tumors. The company partners with research institutions such as the City of Hope National Medical Center (COH) and Nationwide Children's Hospital. Mustang's strategy involves licensing technologies, supporting preclinical and clinical research activities by its partners, and developing product candidates through to potential approval. Mustang is developing a CAR T therapy for solid tumors, MB-101, in partnership with COH, which targets IL13Rα2. Additionally, the company has partnered with Nationwide for MB-108, a herpes simplex virus type 1 (HSV-1) oncolytic virus, designed to enhance the activity of MB-101 for treating patients with high-grade malignant brain tumors. The Phase 1 clinical trial for MB-101, sponsored by COH (ClinicalTrials.gov Identifier: NCT02208362), has completed its treatment phase, with patients undergoing long-term safety assessment. Similarly, the Phase 1 clinical trial for MB-108, sponsored by the University of Alabama at Birmingham (UAB) (ClinicalTrials.gov Identifier: NCT03657576), has also completed its treatment phase, with patients continuing to be assessed for long-term safety. In October 2023, the FDA accepted Mustang's Investigational New Drug (IND) application for the combination of MB-101 and MB-108, referred to as MB-109. This combination is for the treatment of patients with IL13Rα2+ relapsed or refractory glioblastoma (GBM) and high-grade astrocytoma. Following the termination of its cell processing facility lease in Worcester, MA, Mustang is exploring with COH and Nationwide the possibility of initiating this clinical trial as an investigator-sponsored single-institution study at COH in the second quarter of 2026.

Mustang Bio, Inc. (NASDAQ:MBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for MBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for MBIO spans PRE 14A, 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Mustang Bio Seeks 1-for-5 to 1-for-30 Reverse Split to Hold Nasdaq Listing
  • Mustang Bio Q3 2026: $14.3M Cash, Wider Loss, New Nasdaq MVLS Delisting Risk
  • Mustang Bio Gets Second Nasdaq Grace Period to April 12, 2027; Reverse Split on the Table
  • Mustang Bio Receives Nasdaq Delisting Notice; Reports Widened Quarterly Net Loss
  • Mustang Bio Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price, Faces October Deadline

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$1.92M
Diluted EPS
-$0.39
Op. Cash Flow
-$5.26M
Operating Income
-$2.43M
Cash & Equivalents
$17.27M
Debt / Equity
0.00×
Shares Outstanding
4.91M sh
Source: 10-K · filed 2026-03-19 · accession 0001104659-26-032063

Short Interest & Short Volume

2.76 days to cover

FINRA reported short interest of 70,238 shares in MBIO as of the October 30, 2026 settlement, a 19.3% increase from the prior period — about 2.8 days to cover at its recent average daily volume. On November 20, 2026, 32.7% of MBIO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)70,238 shares as of October 30, 2026
Change vs prior period▲ 19.3%
Days to cover2.76 at avg daily volume of 25,449
Daily short volume (FINRA facilities)32.7% of 10,270 shares on November 20, 2026
5-day average short volume19.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$0.2901 -18.07% today
52-week range · as of 2026-11-20 $0.2901 – $1.43
Market cap
$2.69M
Volume
90.6K (2.3× avg)
3-mo avg 38.8K
Live data · 2026-11-21 19:48 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MBIO - Latest Insights

MBIO
Nov 20, 2026, 4:05 PM EST
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.3541
Real-time Price: $0.2901 info
Change: -$0.064 (-18%) info
Market Cap: $2.686M info
MBIO
Nov 05, 2026, 4:09 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.394
Real-time Price: $0.2901 info
Change: -$0.1039 (-26%) info
Market Cap: $2.686M info
MBIO
Oct 15, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3861
Real-time Price: $0.2901 info
Change: -$0.096 (-25%) info
Market Cap: $2.686M info
MBIO
May 05, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.774
Real-time Price: $0.2901 info
Change: -$0.4839 (-63%) info
Market Cap: $2.686M info
MBIO
Apr 17, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.770
Real-time Price: $0.2901 info
Change: -$0.4799 (-62%) info
Market Cap: $2.686M info
MBIO
Mar 19, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.8499
Real-time Price: $0.2901 info
Change: -$0.5598 (-66%) info
Market Cap: $2.686M info
MBIO
Jan 05, 2026, 5:02 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.11
Real-time Price: $0.2901 info
Change: -$0.8199 (-74%) info
Market Cap: $2.686M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets